Aktueller Stand der Diagnostik und Therapie des Equinen Cushing Syndroms

Summary

Equine pituitary pars intermedia dysfunction (PPID) is a common endocrinopathy of aged horses, caused by an adenoma in the pars intermedia of the pituitary gland. The dexamethasone suppression test has been considered as gold standard test for the diagnosis of PPID, but determination of resting ACTH concentrations was besides other diagnostic tests a good alternative. Oral pergolide is used in treatment of PPID and has been shown to be beneficial to reduce the clinical signs.

Key words

Equines Cushing Syndrom - Pituitary Pars Intermedia Dysfunction - Hypophysenadenom - Pergolidmesilat - Dexamethason-Suppressionstest

Literatur

• 1 Couetil L, Paradis M R, Knoll J. Plasma adrenocorticotropin concentration in healthy horses and in horses with clinical signs of hyperadrenocorticism.  J Vet Intern Med. 1996;  10 1-6
• 2 Donaldson M T, LaMonte B H, Morresey P. Treatment with pergolide or cyproheptadine of pituitary pars intermedia dysfunction (equine Cushing's disease).  J Vet Intern Med. 2002;  16 742-746
• 3 Dybdal N O, Hargreaves K M, Madigan J E. Diagnostic testing for pituitary pars intermedia dysfunction in horses.  J Am Vet Med Assoc. 1994;  204 627-632
• 4 Frank N, Andrews F M, Sommardahl C S. Evaluation of the combined dexamethasone suppression/thyrotropin-releasing hormone stimulation test for detection of pars intermedia pituitary adenomas in horses.  J Vet Intern Med. 2006;  20 987-993
• 5 Haritou S J, Zylstra R, Ralli C. Seasonal changes in circadian peripheral plasma concentrations of melatonin, serotonin, dopamine and cortisol in aged horses with Cushing's disease under natural photoperiod.  J Neuroendocrinol. 2008;  20 988-996
• 6 McFarlane D. Endocrine and Metabolic Diseases. In: Smith B, ed. Large Animal Internal Medicine. St. Louis, MO: Mosby Elsevier; 2009: 1339-1344
• 7 Sojka J. Pituitary Pars intermedia Dysfunction. In: Robinson N, Sprayberry K, eds. Current Therapy in equine Medicine 6. St. Louis, MO: Saunders Elsevier; 2009: 732-735
• 8 McFarlane D, Toribio R. Pituitary Pars intermedia Dysfunction (Equine Cushing's Disease). In: Reed S, Bayly W, Sellon D, eds. Equine internal Medicine. St. Louis, MO: Saunders Elsevier; 2010: 1262-1270
• 9 McGowan C M, Neiger R. Efficacy of trilostane for the treatment of equine Cushing's syndrome.  Equine Vet J. 2003;  35 414-418
• 10 McGowan C M, Frost R, Pfeiffer D U. Serum insulin concentrations in horses with equine Cushing's syndrome: response to a cortisol inhibitor and prognostic value.  Equine Vet J. 2004;  36 295-298
• 11 Miller M A, Pardo I D, Jackson L P. Correlation of pituitary histomorphometry with adrenocorticotrophic hormone response to domperidone administration in the diagnosis of equine pituitary pars intermedia dysfunction.  Vet Pathol. 2008;  45 26-38
• 12 Perkins G A, Lamb S, Erb H N. Plasma adrenocorticotropin (ACTH) concentrations and clinical response in horses treated for equine Cushing's disease with cyproheptadine or pergolide.  Equine Vet J. 2002;  34 679-685
• 13 Schott H C, Graves E A, Refsal K R. Diagnosis and treatment of pituitary pars intermedia dysfunction (classical Cushing's disease) and metabolic syndrome (peripheral Cushing's Syndrom) in horses.  Adv Vet Derm. 2005;  5 159-169